Table 2.

The incidence of IFD and breakthrough of IFD in patients who received posaconazole as a prophylaxis drug for 4 days or more.

Index	Posaconazole as a prophylaxis drug continuously used for more than 4 days (N = 445)	Breakthrough rate (%)	95% CI
IFD final diagnostic level
Probable IFD	7	1.6%	0.6%–3.2%
Possible IFD	27
Unclassified IFD	29
Non-IFD patients	382
IFD final diagnostic level of AML/MDS patients who received induction chemotherapy
Probable IFD	2	2.6%	0.3%–9.0%
Possible IFD	6
Unclassified IFD	7
Not IFD	63
IFD final diagnostic level of patients who received HSCT
Probable IFD	4	2.2%	0.6%–5.5%
Possible IFD	16
Unclassified IFD	11
Not IFD	153